LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-231 | HG-6-64-01 | 3.33 | uM | LJP6 | 72 | hr | 1311 | 1901 | 4935 | 0.3851 | 0.2131 |
| MDA-MB-231 | HG-6-64-01 | 10 | uM | LJP6 | 72 | hr | 1311 | 824 | 4935 | 0.1671 | -0.2188 |
| MDA-MB-231 | Neratinib | 0.04 | uM | LJP5 | 72 | hr | 1311 | 4830 | 5079 | 0.9507 | 0.9487 |
| MDA-MB-231 | Neratinib | 0.12 | uM | LJP5 | 72 | hr | 1311 | 4784 | 5079 | 0.9415 | 0.9386 |
| MDA-MB-231 | Neratinib | 0.37 | uM | LJP5 | 72 | hr | 1311 | 4362 | 5079 | 0.8587 | 0.8499 |
| MDA-MB-231 | Neratinib | 1.11 | uM | LJP5 | 72 | hr | 1311 | 4307 | 5079 | 0.8480 | 0.8379 |
| MDA-MB-231 | Neratinib | 3.33 | uM | LJP5 | 72 | hr | 1311 | 3674 | 5079 | 0.7231 | 0.6938 |
| MDA-MB-231 | Neratinib | 10 | uM | LJP5 | 72 | hr | 1311 | 2940 | 5079 | 0.5791 | 0.5118 |
| MDA-MB-231 | JW-7-24-1 | 0.04 | uM | LJP6 | 72 | hr | 1311 | 4188 | 4935 | 0.8487 | 0.8354 |
| MDA-MB-231 | JW-7-24-1 | 0.12 | uM | LJP6 | 72 | hr | 1311 | 4468 | 4935 | 0.9054 | 0.8985 |
| MDA-MB-231 | JW-7-24-1 | 0.37 | uM | LJP6 | 72 | hr | 1311 | 4183 | 4935 | 0.8474 | 0.8334 |
| MDA-MB-231 | JW-7-24-1 | 1.11 | uM | LJP6 | 72 | hr | 1311 | 3842 | 4935 | 0.7784 | 0.7539 |
| MDA-MB-231 | JW-7-24-1 | 3.33 | uM | LJP6 | 72 | hr | 1311 | 3476 | 4935 | 0.7043 | 0.6645 |
| MDA-MB-231 | JW-7-24-1 | 10 | uM | LJP6 | 72 | hr | 1311 | 1172 | 4935 | 0.2376 | -0.0587 |
| MDA-MB-231 | Dasatinib | 0.04 | uM | LJP5 | 72 | hr | 1311 | 2371 | 5079 | 0.4666 | 0.3530 |
| MDA-MB-231 | Dasatinib | 0.04 | uM | LJP6 | 72 | hr | 1311 | 1256 | 4935 | 0.2545 | -0.0238 |
| MDA-MB-231 | Dasatinib | 0.12 | uM | LJP5 | 72 | hr | 1311 | 1229 | 5079 | 0.2420 | -0.0330 |
| MDA-MB-231 | Dasatinib | 0.12 | uM | LJP6 | 72 | hr | 1311 | 899 | 4935 | 0.1822 | -0.1799 |
| MDA-MB-231 | Dasatinib | 0.37 | uM | LJP5 | 72 | hr | 1311 | 927 | 5079 | 0.1824 | -0.1632 |
| MDA-MB-231 | Dasatinib | 0.37 | uM | LJP6 | 72 | hr | 1311 | 916 | 4935 | 0.1858 | -0.1715 |
| MDA-MB-231 | Dasatinib | 1.11 | uM | LJP5 | 72 | hr | 1311 | 950 | 5079 | 0.1872 | -0.1523 |
| MDA-MB-231 | Dasatinib | 1.11 | uM | LJP6 | 72 | hr | 1311 | 877 | 4935 | 0.1780 | -0.1901 |
| MDA-MB-231 | Dasatinib | 3.33 | uM | LJP5 | 72 | hr | 1311 | 956 | 5079 | 0.1884 | -0.1492 |
| MDA-MB-231 | Dasatinib | 3.33 | uM | LJP6 | 72 | hr | 1311 | 874 | 4935 | 0.1773 | -0.1913 |
| MDA-MB-231 | Dasatinib | 10 | uM | LJP5 | 72 | hr | 1311 | 1080 | 5079 | 0.2127 | -0.0947 |